Dr. Nicolas G. Zouain is the Chief of Department of Radiation Oncology at the Clemenceau Medical Center, Beirut, Lebanon. He trained at different prestigious North American institutions like McGill University, University of Montreal, Staten Island University Hospital in New York. He is board certified in three medical specialties: Radiation Oncology, Internal Medicine and Forensic Medicine. He is an Assistant Professor of Radiation Oncology at the University of Central Florida, Faculty of Medicine. He is involved in teaching, research, patient care, management and quality control…
Dr. Nicolas G. Zouain received many research and teaching awards. He was the Program Director of the Department of Radiation Oncology at the American University of Beirut. He was the Chief resident of the Department of Radiation Oncology at the University of Montreal and the Chief Resident of the Department of Internal Medicine at the Staten Island University Hospital in New York.
Dr. Zouain is currently working on many research projects in different areas of cancer treatment. He has many publications in different medical journals. He is a member of many medical societies. He is on the editorial board of many medical journals. Dr. Nicolas G. Zouain gave many medical conferences at different institutions, hospitals and medical meetings (ASTRO, Staten Island University Hospital, University of Montreal, McGill University, University of North Dakota, Saint-Joseph University, American University of Beirut…). He was a member of many cancer committees: Breast cancer study group, Prostate cancer committee, Lung Cancer committee, medical research committee at Sanford Health System.
Dr. Nicolas G. Zouain believes in multidisciplinary approach in the treatment of cancer. Dr. Nicolas Zouain is the first radiation oncologist worldwide to use the new Varian® Capri® High Dose rate applicator for the treatment of rectal cancer.
-[18F]-FDG uptake dose-response correlates with radiation pneumonitis in lung cancer patients. McCurdy MR, Castillo R, Martinez J, Al Hallack MN, Lichter J, Zouain N, Guerrero T. Radiotherapy and Oncology. (The Green Journal) 2012 Jul;104(1):52-7. doi: 10.1016/j.radonc.2012.04.003. Epub 2012 May 10.
-Raval M, Zouain N: “The effectiveness of high dose rate brachytherapy using a special applicator set with external beam radiation treatment and chemotherapy followed by surgery as a treatment of adenocarcinoma of the esophagus: A case series of single institution with literature review”. Journal of Cancer Research and Experimental Oncology Vol. 3(1), pp. 1-7, January 2011.
-Al Hallak M.N, Zouain N: “Cervical and Vulvar Intraepithelial Neoplasia after treatment with oral isotretinoin for severe acne vulgaris: A Case Report”. Case Rep Dermatology 2009; 1:49-51.
-Al Hallak M.N, Zouain N: “Extramammary Perineal Paget’s disease”. Case Rep Gastroenterology 2009; 3: 332-337.
-Al Hallak M.N, Zouain N, McCurdy M, Hayes J: “The level of Europium-15 contaminating the 153Samarium-EDTMP activates the radiation alarm system at the US Homeland Security checkpoints’’. Case Rep Oncology 2009 ; 2 :157-161.
-Hayes J, Pfund J, Zouain N: “Detection of Europium-154 in Patients Post Samarium153 EDTMP Therapy Using a Clinical Gamma Camera”. Health Physics; 98(3): 537-541; 2010.
-McCurdy M, Zouain N: “Successful treatment of primary vaginal papillary serous adenocarcinoma using chemoradiation followed by brachytherapy”. Case Rep Oncology: 2009;2:97–102.
-Sturgeon J, Zouain N: “A Survey of Androgen Deprivation Patterns of Practice in Prostate Cancer by Radiation Oncologists in the United States”. Presented as an Abstract and Poster at the ASTRO Annual meeting in 2011 in Miami, Florida.
-M.R McCurdy, T. Guerrero, N. Zouain, V. Johnson: “Radiation Pneumonitis: Pulmonary Metabolic Response to Radiation in Lung Cancer Patients” . Presented as an Abtract and Poster at the ASTRO Annual meeting 2009 in Chicago, Illinois.
-“Case report of vaginal primary cancer treated with radiation treatment IMRT and HDR Brachytherapy and concomitant chemotherapy”: a presentation at the annual meeting of University of North Dakota, School of Medicine. This manuscript received the Frank Low research award in 2008.
-“The role of autopsy as quality improvement and teaching tool”: American College of Physician national meeting of 1999.
-“The Minimally Invasive Autopsy”: Richmond Medical Community and American College of Physician local meeting, New York 2000.
-Practice guidelines review for the treatment of Non-Small Cell Lung Cancer. “Treatment of Non Small Lung Cancer with combined radiation-gemcitabine”: a literature review for Lilly® pharmaceutical: 2003.
-Thesis: “Gunshot wounds to the head”: Mentor: Prof. Proust; New York, 1999. Thesis presented for the Forensic Medicine Diploma, in Rouen, France.
-Thesis: “Cutaneous melanoma”: Mentor: Prof. Farran; Beirut, 1997. Thesis presented forthe Doctor of Medicine diploma in Beirut, Lebanon.
-2015: Research grant from AUB for studying craniospinal radiation effect on squeletal growth in sheep.
-2015: Research grant from Julphar® to study treatment of Radiation dermatitis. Study currently recruiting patients at AUBMC.
-2010-2011: Research grant from Varian®.
-2006-2009: Research grant from Sanford Health System, Fargo, North Dakota and University of North Dakota, Fargo, North Dakota.
-2003: Research grant from Lilly®.
-2002: Research grant from Pfizer®.
Research Awards :
-Frank Low research award from the University of North Dakota, School of Medicine: 2008.
-Recipient of a Research Award for the research project of the “Minimally Invasive Autopsy” from the Staten Island University Hospital, New York: 2002.
-Recipient of a Certificate of Achievement from the American Medical Association: 2001.
-Research award at the American College of Physician national meeting for “The role of the autopsy as quality improvement and teaching tool”:2000.
Research Experience and Research Projects:
-2001- Present: Participation and recrutement of cancer patients in many clinical trials of the RTOG, COG, NCIC, NCI, NSABP: Staten Island University Hospital, University of Montreal, McGill University and Sanford Health System.
-2008-2010: Retrospective study on the treatment of locally advanced esophageal cancer with a combination of high dose brachytherapy followed by chemo-radiation using IMRT. (published).
-2009-2011: Retrospective study on specific mortality of patients treated with prostate seeds implants for prostate cancer: University of North Dakota, School of Medicine,Fargo, North Dakota: submitted for publication.
-2007-2010: Study on the contamination of Samarium 153 with Europium 154 in patients treated for bone metastases: Retrospective study done with the medical residents and physics department of Sanford Health System, Fargo, North Dakota. (published in 2 manuscripts).
-2011-2013: Retrospective study on prostate cancer patients treated with HDR Brachytherapy at Sanford Health System, Fargo, North Dakota: submitted forpublication.
-2003: Writing of a grant proposal for a phase I/II clinical trial for the treatment of Glioblastoma with Radiation and Gemcitabine.
-2002: Writing of a grant proposal for a phase I/II clinical trial for the treatment of low grade glioma with Radiation and erythropoietin.
-2002-2005: Participation in a study of a dose escalation for the prostate cancer: University of Montreal, Quebec.
-1998-2002: The “Minimally Invasive Autopsy” project: Laparoscopic and needle biopsy autopsy under ultrasound: Staten Island University Hospital, Staten Island, New York. This was a major research project done during my residency in Internal Medicine. This research project was done under the supervision of Pr. McGinn. The goal of the project was to develop alternatives to the traditional open autopsy and to use the autopsies as a teaching tool for the medical residents.
-2001: Participation in a study on the influence of music on the hormones: Wagner College, New York.
-2000: Research on the prevalence of fungal infections in the intensive care unit: Pfizer® research grant, New York. Study done under the supervision of Pr. Glazer.
-2000: Treatment of HIV patients with Dinitrochlorobenzene (DNCB), Diphenylcyopropenone (DNCP) and squaric acid skin patches; phase I/ II clinical trial: Staten Island University Hospital, New York. Study done under the supervision of Dr. Levy.
-1999-2001: Treatment of Hansen’s disease with IL 12; phase I/II clinical trial: Staten Island University Hospital, New York. Study done under the supervision of Dr. Levy.